Group 1 - The company, Lai Kai Pharmaceutical-B (02105), has initiated the enrollment of subjects for a Phase I multi-dose expansion study of LAE102 for the treatment of obesity in China [1] - The Phase I study is a randomized, double-blind, placebo-controlled trial aimed at evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of LAE102 (subcutaneous injection) in 60 overweight/obese subjects [1] - Subjects will be randomly assigned to either the LAE102 group or the placebo group, receiving treatment for a duration of 6 months [1] Group 2 - The multi-dose expansion study is designed to further assess the efficacy and safety characteristics of LAE102 after longer-term treatment, building on positive one-month treatment results observed in a previous MAD study [1] - The company is committed to providing this precision treatment for patients with obesity or metabolic diseases who require new therapeutic options [1]
来凯医药-B：LAE102针对治疗肥胖症的I期多剂量扩展研究完成首例受试者给药